ArticleGenes & genomics2026
Multiple machine learning algorithms construct cuproptosis genes and oxidative stress genes-related LncRNAs signature with prognostic and therapeutic relevance in ovarian cancer.
Article in Genes & genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundCuproptosis and oxidative stress (COS) are emerging regulators in cancer biology. However, their link to long non-coding RNAs (lncRNAs) and clinical outcomes in ovarian cancer remains unclear.
objectiveThis study aimed to construct and validate a prognostic signature based on COS-related lncRNAs to improve risk stratification and provide insights into therapeutic strategies for ovarian cancer.
methodsRNA-seq and clinical data from TCGA and GEO were analyzed to identify COS-related lncRNAs via WGCNA and Pearson correlation. Prognostic lncRNAs were screened using Cox regression and modeled using multiple machine learning algorithms. Immune profiles, mutation patterns, drug sensitivity, and experimental validation were performed.
resultsA 12-lncRNA signature was established that stratified patients into high- and low-risk groups with significant survival differences (HR = 22.6145, p < 0.001). The model showed strong predictive performance (AUCs: 0.91/0.967/0.974) and was validated externally. High-risk patients exhibited greater mutation burden, altered immune pathways (interferon, TGF-β), and differential predicted sensitivity to agents like Axitinib and Pazopanib. RT-qPCR confirmed the expression patterns of 11 out of 12 lncRNAs.
conclusionThis study proposes a robust 12-lncRNA signature linking cuproptosis and oxidative stress with prognosis and therapy response in ovarian cancer, offering preliminary insights for personalized treatment guidance.
Indexed as
Identifiers
41307823What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.